Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu XJ, Cong Y, Zheng R, Li M, Xiu Z, Hu PF, Wu GH, Lianhua CG, Wan Q. Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic. World J Cardiol 2026; 18(11): 124181 [DOI: 10.4330/wjc.124181]
World J Cardiol. Nov 26, 2026; 18(11): 124181 Published online Nov 26, 2026. doi: 10.4330/wjc.124181
Xin-II shows cardioprotective effects in a rat model of chronic heart failure: An integrated network pharmacology and transcriptomic
Xi-Ju Liu, Yan Cong, Ran Zheng, Ming Li, Zhi Xiu, Peng-Fei Hu, Guo-Hua Wu, Cha-Gan Lianhua, Quan Wan
Xi-Ju Liu, Yan Cong, Ran Zheng, Ming Li, Zhi Xiu, School of Clinical Medicine, Inner Mongolia Minzu University, Tongliao 028000, Inner Mongolia Autonomous Region, China
Peng-Fei Hu, Guo-Hua Wu, Cha-Gan Lianhua, Quan Wan, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, TongLiao 028000, Inner Mongolia Autonomous Region, China
Co-corresponding authors: Cha-Gan Lianhua and Quan Wan.
Author contributions: Liu XJ was instrumental and responsible for data re-analysis and re-interpretation, figure plotting, comprehensive literature search, preparation and submission of the current version of the manuscript; Liu XJ and Lianhua CG contributed to formal analysis; Liu XJ and Wan Q contributed to conducting the research, and writing original draft; Cong Y contributed to validation, visualization; Zheng R, Li M, Xiu Z and Hu PF contributed to data curation; Li M, Xiu Z and Wu GH contributed to investigation; Lianhua CG and Wan Q contributed to conceptualization and methodology as co-corresponding authors; Wan Q contributed to designing the research, project administration, writing-review and editing; all of the authors read and approved the final version of the manuscript to be published.
AI contribution statement: No AI tools were used to create the content of this manuscript.
Supported by The Youth Research Start-up Fund of the Affiliated Hospital of Inner Mongolia University for Nationalities, No. 2020QNJJ02.
Institutional animal care and use committee statement: The requirement for ethics approval was approved by the Animal Ethics Committee of Affiliated Hospital of Inner Mongolia Minzu University (approval No. NM-LL-2026-05-15-01).
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The raw RNA-seq data generated in this study have been deposited in the NCBI Gene Expression Omnibus under accession number GSE347459 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE347459) and will be publicly available upon publication. All other data supporting the findings of this study are available within the article and its Supplementary material.
Corresponding author: Quan Wan, PhD, Associate Chief Physician, Department of Cardiovascular Medicine, Affiliated Hospital of Inner Mongolia Minzu University, No. 1742 East Section of Huolinghe Street, TongLiao 028000, Inner Mongolia Autonomous Region, China. wanquan120@126.com
Received: June 9, 2026 Revised: August 13, 2026 Accepted: November 2, 2026 Published online: November 26, 2026 Processing time: 163 Days and 1.2 Hours
Abstract
BACKGROUND
Chronic heart failure (CHF) is a major global public health burden. Mongolian Medicine Xin-II has shown promising clinical efficacy in the management of cardiovascular diseases, including coronary heart disease and arrhythmias. However, its underlying molecular mechanisms remain poorly understood.
AIM
To evaluate the therapeutic effects of Xin-II on CHF and investigate the potential molecular pathways underlying these effects using an integrated approach combining network pharmacology and transcriptomic sequencing.
METHODS
A rat model of CHF was established to assess the therapeutic efficacy of Xin-II. Network pharmacology was used to screen the active components of Xin-II and predict its potential therapeutic targets and key signaling pathways implicated in CHF. Transcriptomic sequencing (RNA-seq) was performed to characterize drug-induced changes in gene expression and further verify the regulatory patterns of candidate signaling pathways identified by network pharmacology.
RESULTS
Xin-II improved cardiac function and mitigated myocardial pathological lesions in rats with CHF. Transcriptomic analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment identified the peroxisome proliferator-activated receptor (PPAR) signaling pathway as the most significantly enriched pathway, suggesting its potential involvement in the therapeutic effects of Xin-II against CHF. Mechanistically, Xin-II modulated the expression of key genes and proteins associated with the PPAR/hypoxia-inducible factor-1 alpha signaling cascade. These findings suggest that Xin-II attenuates CHF through multitarget regulation, with the PPAR/hypoxia-inducible factor-1 alpha axis potentially highlighting an important mechanistic pathway.
CONCLUSION
This study found that XinII ameliorates CHF through multi-target molecular mechanisms, thereby providing insights into the therapeutic effects of Xin-II and supporting its further investigation as a treatment for CHF. Further, these findings establish a valuable paradigm to advance the modernization and broader application of traditional Mongolian medicine.
Core Tip: This study integrates network pharmacology and RNA-seq to reveal that Mongolian Medicine Xin-II alleviates chronic heart failure by modulating the peroxisome proliferator-activated receptor/hypoxia-inducible factor-1 signaling pathway, improving cardiac function and myocardial pathology.